Abstract 12493: Impact of Ticagrelor Re-Load on Pharmacodynamic Profiles in Patients on Maintenance Ticagrelor Therapy

Background: Although ticagrelor is associated with superior clinical efficacy than clopidogrel, ticagrelor-treated patients may still require subsequent revascularization procedures, either due to acute or chronic progression of atherosclerotic disease. However, the optimal dosing regimen of ticagrelor to be administered among patients already on maintenance therapy has been questioned. Methods: This was a prospective, randomized, double-blind study assessing the pharmacodynamic (PD) effects of two dosing regimens of ticagrelor among patients already on standard aspirin (81 mg/qd) and ticagrelor (90 mg bid) maintenance therapy for at least 14 days. Patients were randomized to either 90 mg (MD group; one 90 mg tablet and one matching placebo) or 180 mg (LD group; two 90 mg tablets). Study treatment was administered 12 hours after the last maintenance dose (timing of trough PD level). PD assessments were conducted at 3 time-points (baseline, 1 hour and 4 hours after administration of randomized treatment) u...